These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2889460)

  • 1. The effects and dose-response relationship of xamoterol in patients with ischaemic heart disease.
    Molajo AO; Bennett DH; Marlow HF; Snow HM; Bastain W
    Br J Clin Pharmacol; 1987 Sep; 24(3):373-9. PubMed ID: 2889460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of xamoterol, a beta 1 adrenoceptor partial agonist, in patients with ischaemic dysfunction of the left ventricle.
    Vigholt-Sørensen E; Faergeman O; Snow HM
    Br Heart J; 1989 Nov; 62(5):335-41. PubMed ID: 2574049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of xamoterol a new beta-adrenoceptor partial agonist, in patients with angina pectoris.
    Barrios L; Geboers J; Piessens JH; de Geest H
    Eur J Clin Pharmacol; 1986; 29(6):667-71. PubMed ID: 2872055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of xamoterol (ICI 118587), a new beta1 adrenoceptor partial agonist, on resting haemodynamic variables and exercise tolerance in patients with left ventricular dysfunction.
    Molajo AO; Bennett DH
    Br Heart J; 1985 Jul; 54(1):17-21. PubMed ID: 2861834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The value of xamoterol in moderate ischemic cardiac insufficiency].
    Rousseau MF; Cheron P; Vincent MF; Pouleur H; Lavenne F
    Ann Cardiol Angeiol (Paris); 1984; 33(4):215-8. PubMed ID: 6147115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure.
    Virk SJ; Davies MK
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):15S-22S. PubMed ID: 2572250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xamoterol in severe congestive heart failure: long-term oral treatment, a double-blind randomised study.
    Tangø M; Lyngborg K; Mehlsen J; Svendsen TL; Trap-Jensen J
    Int J Cardiol; 1992 Jan; 34(1):63-8. PubMed ID: 1347763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Placebo controlled trial of xamoterol versus digoxin in chronic atrial fibrillation.
    Ang EL; Chan WL; Cleland JG; Moore D; Krikler SJ; Alexander ND; Oakley CM
    Br Heart J; 1990 Oct; 64(4):256-60. PubMed ID: 1977430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute and chronic hemodynamic effects of xamoterol in mild to moderate congestive heart failure.
    Virk SJ; Qiang FX; Anfilogoff NH; Murray RG; Littler WA; Davies MK
    Am J Cardiol; 1991 May; 67(12):48C-52C; discussion 52C-54C. PubMed ID: 1673587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of xamoterol, a beta 1-adrenoceptor partial agonist, in mild to moderate heart failure. U.K. Xamoterol Study Group.
    Waller DG; Webster J; Sykes CA; Bhalla KK; Wray R
    Eur Heart J; 1989 Nov; 10(11):1003-10. PubMed ID: 2574108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of xamoterol, a beta 1-adrenoceptor partial agonist, on myocardial pH decreased by coronary occlusion in dogs.
    Sashida H; Sakai K; Hino T; Abiko Y
    Pharmacology; 1986; 33(6):301-10. PubMed ID: 2882527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of left ventricular contractility and relaxation with the beta 1-adrenergic receptor partial agonist xamoterol at rest and during exercise in patients with postinfarction left ventricular dysfunction. A placebo-controlled randomized trial.
    de Feyter PJ; Serruys PW; Suryapranata H
    Circulation; 1990 Feb; 81(2 Suppl):III99-106. PubMed ID: 1967562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation.
    Lewis RV; McMurray J; McDevitt DG
    J Cardiovasc Pharmacol; 1989 Jan; 13(1):1-6. PubMed ID: 2468920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group.
    Lancet; 1990 Jul; 336(8706):1-6. PubMed ID: 1694945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ischaemic left ventricular failure: evidence of sustained benefit after 18 months' treatment with xamoterol.
    Vigholt-Sørensen E; Faergeman O
    Br Heart J; 1990 Sep; 64(3):186-9. PubMed ID: 1976339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exercise capacity, arrhythmias, humoral and chemical parameters during long-term therapy with xamoterol.
    Erlemeier HH; Kupper W; Bleifeld W
    Int J Cardiol; 1990 Aug; 28(2):197-208. PubMed ID: 1697569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xamoterol in hypertrophic cardiomyopathy: effects on diastolic function and heart rate.
    Gilligan DM; Stewart R; Chan WL; Oakley CM
    Int J Cardiol; 1992 Jun; 35(3):377-86. PubMed ID: 1351887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of chronic oral administration of xamoterol to patients with severe heart failure treated with ACE inhibitors.
    Pouleur H; Hanet C; Rousseau MF
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):82S-83S. PubMed ID: 2572263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective beta-1-adrenoceptor partial agonist treatment for congestive heart failure.
    Shabetai R
    Cardiology; 1990; 77(5):357-66. PubMed ID: 1981492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xamoterol in patients with dilated cardiomyopathy: an increase in beta-receptors in lymphocytes.
    Watanabe K; Hirokawa Y; Shibata A
    J Cardiol; 1988 Dec; 18(4):1015-25. PubMed ID: 2908309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.